Safe Orthopaedics, a spine company based in Eragny-sur-Oise, France, has announced that it has now sold more than 10,000 surgical kits worldwide since they were first launched. Safe Orthopaedics’ sterile kits all include single-use instruments and at least one vertebral implant.
Safe Orthopaedics Hits 10,000 Surgical Kit Mark
2 min read Premium comments
Secondary#safeorthopaedics#sterispine
According to the company, “The number of surgeries performed using Safe Orthopaedics’ kits in France has risen above 6,000, after an acceleration in 2017.”
“The factors driving this substantial increase include additions to the sales team, which has expanded from four to seven staff, and rapid adoption of SteriSpine PS technology for the treatment of all types of fracture (accidental, metastatic and osteoporotic).”
“In 2017, the company doubled its market share in this core segment in France to reach 8%.”
“Selling our 10,000th surgical kit represents a major milestone for Safe Orthopaedics, and we wanted to take the opportunity to thank all the surgeons who use our products for their trust and continuing loyalty to our technology. We would also like to thank our shareholders—without them, we would not have been able to develop our concept into the internationally adopted product it is today,” said Pierre Dumouchel, company CEO and co-founder.
“We are delighted that more than 10,000 patients have been able to reap the benefit of our safer technology, and we are confident that we will be able to replicate in Germany our fine accomplishments in France and identify other international development opportunities while continuing to expand our sales teams.”
Pierre Dumouchel told OTW, ““Our growth was 37% in 2017 and we expect to accelerate even more over the next 12 months by deepening our commercial footprint on our major European markets.”
“In France, Safe Orthopaedics doubled its market share in 2017, from 4 to 8%, with four sales representatives. As of 2018, we have seven sales reps on this market. In Germany, a direct sales force was implemented last year. We are expecting great commercial results on this market, which is seven times bigger then the French market in value and four times in volume. In the UK, we have been working a distributor with great results. And we are considering additional opportunities to drive a solid growth on the European market.”
“So, to summarize: our technology has obtained sufficient recognition to now rapidly develop our sales force on our main markets.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.